Abstract
Compounds acting in the ventral tegmental area to increase motor activity are thought to do so by activating mesolimbic dopamine transmission. The present report demonstrates that the microinjection of N-methyl-d-aspartate (NMDA) antagonists into the ventral tegmental area produces a dose-dependent increase in motor activity. This effect was not mimicked by antagonizing either α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate or metabotropic glutamate receptors in the ventral tegmental area. Three experiments were conducted that indicated that the capacity of NMDA receptor antagonists to elevate motor activity did not involve increased dopamine transmission. 1) The systemic administration of a D1 dopamine receptor antagonist did not inhibit the motor stimulant response to NMDA antagonist injection into the ventral tegmental area except at doses that also inhibited motor activity after an injection of saline into the ventral tegmental area. 2) Stimulating orphanin receptors in the ventral tegmental area selectively inhibits dopamine cells, and this did not alter NMDA antagonist-induced motor activity. Whereas, stimulating γ-aminobutyric acid (GABA)B receptors hyperpolarizes both dopamine and GABA cells in the ventral tegmental area, and this abolished NMDA antagonist-induced motor activity. 3) The microinjection of an NMDA antagonist into the ventral tegmental area did not increase dopamine metabolism in dopamine terminal fields, including the accumbens, striatum, or prefrontal cortex. Also consistent with a lack of dopamine involvement, repeated administration of NMDA antagonist into the ventral tegmental area did not produce behavioral sensitization. These data identify a mechanism to elicit a motor stimulant response from the ventral tegmental area that does not involve activating dopamine transmission.
Footnotes
-
↵1 Current address: Department of Psychobiology, National Institute on Drug Abuse/National Institutes of Health Building C, Room 321, 5500 Nathan Shock Dr., Baltimore, MD 21224. E-mail:jcornish{at}intra.nida.nih.gov
-
This work was supported in part by U.S. Public Health Service Grants DA-03906 and MH-40817.
- Abbreviations:
- VTA
- ventral tegmental area
- NMDA
- N-methyl-d-aspartate
- GABA
- γ-aminobutyric acid
- AMPA
- α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
- CNQX
- 6-cyano-7-nitroquinoxaline-2,3-dione
- AP-5
- 2-amino-5-phosphonopentanoic acid
- MCPG
- (S)-α-methyl-4-carboxyphenylglycine
- CPP
- (3-(R)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid
- DAMGO
- d-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin
- OFQ
- orphanin FQ-nociceptin
- DOPAC
- 3,4-dihydroxyphenyl acetic acid
- HVA
- homovanillic acid
- ANOVA
- analysis of variance
- mGluR
- metabotropic glutamate receptor
- Received November 21, 2000.
- Accepted March 13, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|